The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 138, Issue 1, 2012, Pages 44-49

  Paulson, Lorien ^a   Shindo, Maisie ^a   Schuff, Kathryn ^a   Corless, Christopher ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MOLECULAR MARKER;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MASS SPECTROMETRY; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC MARKERS; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NECK DISSECTION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84855953674     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archoto.2011.226     Document Type: Article

References (35)

1. Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol. 2009;99(4):186-188.
2. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723-5729. (Pubitemid 41415482)
3. Hay I, Bergstralh E, Grant C, et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery. 1999;126(6):1173-1182.
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Associationmanagement guidelines for patients with thyroid nodules and differentiated thyroid cancer [published correction appears in Thyroid. 2010;20(6):674-675]. Thyroid. 2009;19(11):1167-1214.
5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457. (Pubitemid 36373628)
6. Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc. 2010;73(3):113-128.
7. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146(6):1215-1223.
8. Elisei R, Ugolini C, Viola D, et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93(10):3943-3949.
9. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-762. (Pubitemid 350294294)
10. Schmidt J, Derr V, Heinrich MC, et al. BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol. 2007;31(9):1337-1343. (Pubitemid 47329669)
11. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113(8):1749-1755.
12. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-428. (Pubitemid 24345593)
13. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-424.
14. Sato N, Oyamatsu M, Koyama Y, Emura I, Tamiya Y, Hatakeyama K. Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol. 1998;69(3):151-155. (Pubitemid 28549890)
15. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18(4):559-568. (Pubitemid 24273857)
16. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164(6):658-661.
17. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070-1078.
18. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524-531. (Pubitemid 43157614)
19. Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay ID. Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006. World J Surg. 2010;34(6):1239-1246.
20. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94(4):1162-1167.
21. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140(6):1000-1007. (Pubitemid 44937385)
22. Lin JD, Huang MJ, Hsu BR, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol. 2002;80(1):45-51. (Pubitemid 34477735)
23. Moo TA, Fahey TJ III. Lymph node dissection in papillary thyroid carcinoma. Semin Nucl Med. 2011;41(2):84-88.
24. Palestini N, Borasi A, Cestino L, Freddi M, Odasso C, Robecchi A. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? our experience. Langenbecks Arch Surg. 2008;393(5):693-698.
25. Gemsenjäger E, Perren A, Seifert B, Schüler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197(2):182-190. (Pubitemid 36927380)
26. Shindo M, Stern A. Total thyroidectomy with and without selective neck dissection: a comparison off complication rates. Arch Otolaryngol Head Neck Surg. 2010;136(6):584-587.
27. Carling T, Long WD III, Udelsman R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. Curr Opin Oncol. 2010;22(1):30-34.
28. Jain M, Khan A, Patwardhan N, Reale F, Safran M. Follicular variant of papillary thyroid carcinoma: a comparative study of histopathologic features and cytology results in 141 patients. Endocr Pract. 2001;7(2):79-84. (Pubitemid 34145060)
29. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2010;23(9):1201-1208.
30. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(11):4085-4090. (Pubitemid 350074715)
31. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-6379. (Pubitemid 41759286)
32. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-262. (Pubitemid 40896444)
33. Salter KD, Andersen PE, Cohen JI, et al. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. Arch Otolaryngol Head Neck Surg. 2010;136(7):692-696.
34. Lin HW, Bhattacharyya N. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope. 2010;120(4):712-716.
35. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71-77. (Pubitemid 37046372)